First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: A randomized, placebo-controlled study

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Andreasen, Niels ^a   Simeoni, Monica ^b   Ostlund, Henrik ^c   Lisjo, Pia I ^d   Fladby, Tormod ^e   Loercher, Amy E ^f   Byrne, Gerard J ^g   Murray, Frances ^f   Scott Stevens, Paul T ^b   Wallin, Anders ^h   Zhang, Yinghua Y ^f   Bronge, Lena H ⁱ   Zetterberg, Henrik ^j,k   Nordberg, Agneta K ^a   Yeo, Astrid J ^b   Khan, Shahid A ^b   Hilpert, Jan ^l   Mistry, Prafull C ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Clinical Operations   (Sweden)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Aleris Diagnostics   (Sweden)

^j UNIVERSITY OF GOTHENBURG   (Sweden)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l GLAXOSMITHKLINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; GSK 933776; PLACEBO; UNCLASSIFIED DRUG; ALLOANTIBODY; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; ADVERSE OUTCOME; AGED; ALZHEIMER DISEASE; ARTICLE; BACKACHE; BLEEDING; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; VASOGENIC EDEMA; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ARIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; ISOANTIBODIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84961291985     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098153     Document Type: Article

References (21)

1. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712. doi: 10.1038/nrd3505 PMID: 21852788
2. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070. doi: 10.1212/WNL.0b013e3181c67808 PMID: 19923550
3. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, et al. (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24: 198-203. doi: 10.1097/WAD.0b013e3181c53b00 PMID: 20505438
4. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372. doi: 10.1016/S1474-4422(10)70043-0 PMID: 20189881
5. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, et al. (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69: 1002-1010. PMID: 22473769
6. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, et al. (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69: 198-207. doi: 10.1001/archneurol.2011.1538 PMID: 21987394
7. Sperling R, Salloway S, Raskind M, Ferris S, Liu E, et al. (2012) A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ε4 carriers. Eur J Neurol 19 (Suppl. 1): 70.
8. Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, et al. (2012) A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ε4 non-carriers. Eur J Neurol 19 (Suppl. 1): 70.
9. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333. doi: 10.1056/NEJMoa1304839 PMID: 24450891
10. Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10: 1121-1130. doi: 10.1517/14712598.2010.493872 PMID: 20497044
11. Karran E, Hardy J (2014) Antiamyloid therapy for Alzheimer's disease - are we on the right road? N Engl J Med 370: 377-378. doi: 10.1056/NEJMe1313943 PMID: 24450897
12. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7: 367-385. doi: 10.1016/j.jalz.2011.05.2351 PMID: 21784348
13. th ed. Cambridge, MA: US Department of Health and Human Services.
14. Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CAF, et al. (2014). Modulation of beta amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a Phase I study. Alzheimers Res Ther (in press).
15. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psych Res 12: 189-198.
16. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, et al. (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 10: 1776-1781. PMID: 11568086
17. Zetterberg H, Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352: 67-69. PMID: 14615052
18. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, et al. (2014) Phase III trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370: 311-321 doi: 10.1056/NEJMoa1312889 PMID: 24450890
19. Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, et al. (2011) Prevalence of asymptomatic vasogenic edema in pretreatment of Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7: 396-401. doi: 10.1016/j.jalz.2011.05.2353 PMID: 21784350
20. Davda JP, Hansen RJ (2010) Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs 2: 576-588. doi: 10.4161/mabs.2.5.12833 PMID: 20676036
21. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, et al. (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8: 261-271. doi: 10.1016/j.jalz. 2011.09.224 PMID: 22672770